Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Gillmore

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Biological Regulators and Homeostatic Agents|October 9, 2004
Use of the allogeneic TCR repertoire to enhance anti-tumor immunityS Xue, R Gillmore, L Gao, et al.
Blood Cells, Molecules & Diseases|November 6, 2004
WT1-targeted immunotherapy of leukaemiaS Xue, L Gao, R Gillmore, et al.
British Journal of Cancer|March 2, 2013
A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinomaT Meyer, A Kirkwood, M Roughton, et al.
British Journal of Cancer|March 18, 2010
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumoursN C Turner, S J Strauss, D Sarker, et al.
British Journal of Cancer|September 28, 2016
Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladderS D Kaupp-Roberts, G Yadegarfar, E Friend, et al.
ESMO Open|June 25, 2026
Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trialA Lamarca, D H Palmer, H S Wasan, et al.
British Journal of Cancer|May 1, 2020
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinomaP G Corrie, W Qian, B Basu, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Biological Regulators and Homeostatic Agents|October 9, 2004
Use of the allogeneic TCR repertoire to enhance anti-tumor immunityS Xue, R Gillmore, L Gao, et al.
Blood Cells, Molecules & Diseases|November 6, 2004
WT1-targeted immunotherapy of leukaemiaS Xue, L Gao, R Gillmore, et al.
British Journal of Cancer|March 2, 2013
A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinomaT Meyer, A Kirkwood, M Roughton, et al.
British Journal of Cancer|March 18, 2010
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumoursN C Turner, S J Strauss, D Sarker, et al.
British Journal of Cancer|September 28, 2016
Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladderS D Kaupp-Roberts, G Yadegarfar, E Friend, et al.
ESMO Open|June 25, 2026
Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trialA Lamarca, D H Palmer, H S Wasan, et al.
British Journal of Cancer|May 1, 2020
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinomaP G Corrie, W Qian, B Basu, et al.
Pageof 4